Journal
CANCER CELL
Volume 36, Issue 1, Pages 17-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2019.06.005
Keywords
-
Categories
Funding
- NIH NCI [R01 CA222877, R01 CA208303, R01 CA205001]
- UCLA SPORE in Prostate Cancer [NIH NCI P50 CA092131]
- W.M. Keck Foundation
- UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Hal Gaba Director's Fund for Cancer Stem Cell Research
- UC Tobacco-Related Disease Research Program (TRDRP) [26IP-0036]
- UCLA Medical Scientist Training Program [NIH NIGMS T32 GM008042]
- Systems and Integrative Biology Training Grant at UCLA [NIH T32 GM008185]
- Prostate Cancer Foundation Young Investigator Award
- National Center for Advancing Translational Sciences UCLA CTSI Grant [UL1TR000124]
- UCLA Broad Stem Cell Research Center postdoctoral fellowship
- NIH NCI K99/R00 Pathway to Independence Award [K99 CA218731]
Ask authors/readers for more resources
Small-cell neuroendocrine cancers (SCNCs) are an aggressive cancer subtype. Transdifferentiation toward an SCN phenotype has been reported as a resistance route in response to targeted therapies. Here, we identified a convergence to an SCN state that is widespread across epithelial cancers and is associated with poor prognosis. More broadly, non-SCN metastases have higher expression of SCN-associated transcription factors than non-SCN primary tumors. Drug sensitivity and gene dependency screens demonstrate that these convergent SCNCs have shared vulnerabilities. These common vulnerabilities are found across unannotated SCN-like epithelial cases, small-round-blue cell tumors, and unexpectedly in hematological malignancies. The SCN convergent phenotype and common sensitivity profiles with hematological cancers can guide treatment options beyond tissue-specific targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available